Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2020

Supporting Information

New Cytotoxic Natural Products from the Marine Sponge-Derived Fungus *Pestalotiopsis* sp. by Epigenetic

Modification

Hui Lei¹, Dan Zhang¹, Nan Ding³, Siwei Chen¹, Can Song¹, Yu Luo¹, Xiujuan Fu¹, Xiaoxu Bi^{2*}, and Hong Niu^{1*}

- ¹ School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China;
- ² College of Agriculture and Life Sciences, Kunming University, Kunming, Yunnan 650241, China;
- ³ Institute of Pathogenic Biology, University of South China, Hengyang 421001, China;

*To whom correspondence should be addressed.

Tel/fax: +86-0830-316 2291. E-mail: dawn@nwsuaf.edu.cn

Figure S1. HRESI-MS spectrum of the new compound 1

Figure S2. ¹H NMR (600 MHz, CD₃OD) spectrum of the new compound 1

Figure S3. ¹³C NMR (150 MHz, CD₃OD) spectrum of the new compound 1

Figure S4. HSQC spectrum of the new compound 1

Figure S5. HMBC spectrum of the new compound 1

Figure S6. COSY spectrum of the new compound 1

Figure S7. NOESY spectrum of the new compound 1

Figure S8. HRESI-MS spectrum of the new compound **2**

Figure S9. ¹H NMR (600 MHz, CD₃OD) spectrum of the new compound 2

Figure S10. ¹³C NMR (150 MHz, CD₃OD) spectrum of the new compound 2

Figure S11. HSQC spectrum of the new compound 2

Figure S12. HMBC spectrum of the new compound **2**

Figure S13. COSY spectrum of the new compound 2

Figure S14. NOESY spectrum of the new compound 2

Figure S15. HRESI-MS spectrum of the new compound 3/11

Figure S16. ¹H NMR (600 MHz, CD₃OD) spectrum of the new compound 3/11

Figure S17. ¹³C NMR (150 MHz, CD₃OD) spectrum of the new compound 3/11

Figure S18. Enlarged-1¹³C NMR (150 MHz, CD₃OD) spectrum of the new compound 3/11

Figure S19. Enlarged-2¹³C NMR (150 MHz, CD₃OD) spectrum of the new compound 3/11

Figure S20. HSQC spectrum of the new compound 3/11

Figure S21. HMBC spectrum of the new compound 3/11

Figure S22. COSY spectrum of the new compound 3/11

Figure S23. NOESY spectrum of the new compound 3/11

Figure S24. HRESI-MS spectrum of the new compound 4

Figure S25. ¹H NMR (600 MHz, CD₃OD) spectrum of the new compound 4

Figure S26. ¹³C NMR (150 MHz, CD₃OD) spectrum of the new compound 4

Figure S27. HSQC spectrum of the new compound 4

Figure S28. HMBC spectrum of the new compound 4

Figure S29. COSY spectrum of the new compound 4

Figure S30. NOESY spectrum of the new compound 4

Figure S31. ¹H NMR (600 MHz, CDCl₃) spectrum of the compound **5**

Figure S32. ¹³C NMR (150 MHz, CDCl₃) spectrum of the compound 5

Figure S33. ¹H NMR (600 MHz, CD₃OD) spectrum of the compound 6

Figure S34. ¹³C NMR (150 MHz, CD₃OD) spectrum of the compound 6

Figure S35. HSQC spectrum of the compound 6

Figure S36. HMBC spectrum of the compound 6

Figure S37. COSY spectrum of the compound 6

Figure S38. ¹H NMR (600 MHz, CD₃OD) spectrum of the compound 7

Figure S39. ¹³C NMR (150 MHz, CD₃OD) spectrum of the compound 7

Figure S40. HSQC spectrum of the compound 7

Figure S41. HMBC spectrum of the compound 7

Figure S42. COSY spectrum of the compound 7

Figure S43. NOESY spectrum of the compound 7

Figure S44. ¹H NMR (600 MHz, CD₃OD) spectrum of the compound 8

Figure S45. ¹³C NMR (150 MHz, CD₃OD) spectrum of the compound 8

Figure S46. HSQC spectrum of the compound 8

Figure S47. HMBC spectrum of the compound 8

Figure S48. COSY spectrum of the compound 8

Figure S49. ¹H NMR (600 MHz, CD₃OD) spectrum of the compound **9**

Figure S50. ¹³C NMR (150 MHz, CD₃OD) spectrum of the compound 9

Figure S51. HSQC spectrum of the compound 9

Figure S52. HMBC spectrum of the compound 9

Figure S53. COSY spectrum of the compound 9

Figure S54. NOESY spectrum of the compound **9**

Figure S55. ¹H NMR (600 MHz, CD₃OD) spectrum of the compound **10**

Figure S56. ¹³C NMR (150 MHz, CD₃OD) spectrum of the compound **10**

Figure S57. Chromatogram of the chiral HPLC separation of **3** and **11**.

Figure S58. Chromatogram of the HPLC separation of **2** and **7**

Table S1. ¹H (600 MHz) and ¹³C NMR (150 MHz) data for compounds 1 and 6 in CD₃OD

Table S2. ¹H (600 MHz) and ¹³C NMR (150 MHz) data for compounds 2 and 7 in CD₃OD

Figure S59. Comparison of the calculated ECD spectra for 1 with the experimental spectrum of 1 in methanol

 Table S3. Energy analysis for conformers of 1 at B3LYP/6-31G(d) level

Figure S60. Comparison of the calculated ECD spectra for 2 with the experimental spectrum of 2 in methanol

Table S4. Energy analysis for conformers of **2** at B3LYP/6-31G(d) level

Figure S61. Comparison of the calculated ECD spectra for **3** with the experimental spectrum of **3** in methanol

Table S5. Energy analysis for conformers of **3** at B3LYP/6-31G(d) level

Qualitative Analysis Report

Data Filename	LH-4-NEG.d	Sample Name	
Sample Type	Sample	Position	P1-A2
Instrument Name	Instrument 1	User Name	
Acq Method	default-20191128-neg.m	Acquired Time	7/14/2020 8:55:04 AM
IRM Calibration Status	Success	DA Method	analysis.m
Comment			
Sample Group Info.			

User Spectra



Figure S1. HRESI-MS spectrum of the new compound 1



Figure S2. ¹H NMR (600 MHz, CD₃OD) spectrum of the new compound 1



Figure S3. ¹³C NMR (150 MHz, CD₃OD) spectrum of the new compound 1



Figure S4. HSQC spectrum of the new compound 1



Figure S5. HMBC spectrum of the new compound 1



Figure S6. COSY spectrum of the new compound 1



Figure S7. NOESY spectrum of the new compound 1

Qualitative Analysis Report

Data Filename	LH-2-NEG.d	Sample Name	Unavailable
Sample Type	Unavailable	Position	Unavailable
Instrument Name	Unavailable	User Name	Unavailable
Acq Method		Acquired Time	Unavailable
IRM Calibration Status	Success	DA Method	analysis.m
Comment	Sample information is unavailable		

User Spectra



Figure S8. HRESI-MS spectrum of the new compound 2



Figure S9. ¹H NMR (600 MHz, CD₃OD) spectrum of the new compound **2**



Figure S10. ¹³C NMR (150 MHz, CD₃OD) spectrum of the new compound **2**



Figure S11. HSQC spectrum of the new compound **2**



Figure S12. HMBC spectrum of the new compound **2**



Figure S13. COSY spectrum of the new compound **2**



Figure S14. NOESY spectrum of the new compound **2**

Qualitative Analysis Report

Data Filename	LH-482-POS.d	Sample Name	
Sample Type	Sample	Position	P1-A2
Instrument Name	Instrument 1	User Name	
Acq Method	default-20191128-pos.m	Acquired	7/14/2020 9:35:28 AM
		Time	
IRM Calibration Status	success	DA Method	analysis.m
Comment			

User Spectra



Figure S15. HRESI-MS spectrum of the new compound **3**



Figure S16. ¹H NMR (600 MHz, CD₃OD) spectrum of the new compound **3**



Fiure S17. ¹³C NMR (150 MHz, CD₃OD) spectrum of the new compound **3**



Fiure S18. Enlarged-1 ¹³C NMR (150 MHz, CD₃OD) spectrum of the new compound **3**



Fiure S19. Enlarged-2 ¹³C NMR (150 MHz, CD₃OD) spectrum of the new compound **3**



Figure S20. HSQC spectrum of the new compound **3**



Figure S21. HMBC spectrum of the new compound **3**



Figure S22. COSY spectrum of the new compound **3**



Figure S23. NOESY spectrum of the new compound **3**



Bruker Compass DataAnalysis 4.1	printed:	7/11/2018 3:09:33 PM	by: SCSIO	Page 1 of 1
	per constant.		ey. 00010	Fage For F

Figure S24. HRESI-MS spectrum of the new compound 4



Figure S25. ¹H NMR (600 MHz, CD₃OD) spectrum of the new compound 4



Figure S26. ¹³C NMR (150 MHz, CD₃OD) spectrum of the new compound 4



Figure S27. HSQC spectrum of the new compound 4



Figure S28. HMBC spectrum of the new compound 4



Figure S29. COSY spectrum of the new compound 4



Figure S30. NOESY spectrum of the new compound **4**



Figure S31. ¹H NMR (600 MHz, CDCl₃) spectrum of the compound **5**



Figure S32. ¹³C NMR (150 MHz, CDCl₃) spectrum of the compound **5**



Figure S33. ¹H NMR (600 MHz, CD₃OD) spectrum of the compound **6**



Figure S34. ¹³C NMR (150 MHz, CD₃OD) spectrum of the compound **6**



Figure S35. HSQC spectrum of the compound **6**



Figure S36. HMBC spectrum of the compound **6**



Figure S37. COSY spectrum of the compound **6**



Figure S38. ¹H NMR (600 MHz, CD₃OD) spectrum of the compound 7



Figure S39. ¹³C NMR (150 MHz, CD₃OD) spectrum of the compound 7



Figure S40. HSQC spectrum of the compound 7



Figure S41. HMBC spectrum of the compound 7



Figure S42. COSY spectrum of the compound 7



Figure S43. NOESY spectrum of the compound 7



Figure S44. ¹H NMR (600 MHz, CD₃OD) spectrum of the compound 8



Figure S45. ¹³C NMR (150 MHz, CD₃OD) spectrum of the compound **8**



Figure S46. HSQC spectrum of the compound 8



Figure S47. HMBC spectrum of the compound **8**



Figure S48. COSY spectrum of the compound **8**



Figure S49. ¹H NMR (600 MHz, CD₃OD) spectrum of the compound **9**



Figure S50. ¹³C NMR (150 MHz, CD₃OD) spectrum of the compound **9**



Figure S51. HSQC spectrum of the compound **9**



Figure S52. HMBC spectrum of the compound **9**



Figure S53. COSY spectrum of the compound **9**



Figure S54. NOESY spectrum of the compound **9**



Figure S55. ¹H NMR (600 MHz, CD₃OD) spectrum of the compound **10**

Figure S56. ¹³C NMR (150 MHz, CD₃OD) spectrum of the compound **10**

Figure S57. Chromatogram of the chiral HPLC separation of **3** and **11**.

Figure S58. Chromatogram of the HPLC separation of **2** and **7**.

	1			6
No.	$d_{\rm C}$, type	$d_{\rm H}$ (J in Hz)	$d_{\rm C}$, type	$d_{\rm H} (J \text{ in Hz})$
1	197.3, CH	10.43, s	197.3, CH	10.44, s
2	119.4, C		119.4, C	
3	164.4, C		164.4, C	
4	116.6, CH	6.79, d (8.0)	116.6, CH	6.80, d (8.0)
5	138.3, CH	7.45, t (8.0)	138.3, CH	7.45, t (8.0)
6	122.5, CH	6.85, d (8.0)	122.5, CH	6.85, d (8.0)
7	148.8, C		148.8, C	
8	28.9, CH ₂	3.25, ddd (14.5, 10.4, 4.6)	29.1, CH ₂	3.23, ddd (13.8, 10.3, 4.8)
		3.00, ddd (14.5, 10.1, 6.7)		3.03, ddd (13.8, 10.1, 6.8)
9	37.2, CH ₂	1.94, ddd (13.4, 10.1, 6.6)	36.9, CH ₂	1.82, ddd (14.1, 6.8, 3.4)
		1.69, ddd (13.4, 9.8, 4.6)		1.76, ddd (14.1, 9.4, 4.6)
10	75.9, CH	3.39, ddd (9.0, 5.8, 2.4)	75.6, CH	3.41, ddd (9.4, 5.1, 3.1)
11	71.7, CH	3.59, dd (6.2, 5.8)	71.3, CH	3.65, qd (6.4, 5.1)
12	19.1, CH ₃	1.19, d (6.2)	18.9, CH ₃	1.16, d (6.4)

Table S1. ¹H (600 MHz) and ¹³C NMR (150 MHz) data for compounds 1 and 6 in CD₃OD

	2		7	
No.	$d_{\rm C}$, type	$d_{\rm H} (J {\rm in} {\rm Hz})$	$d_{\rm C}$, type	$d_{\rm H} (J \text{ in Hz})$
1	197.7, CH	10.23, s	197.6, CH	10.21, s
2	118.4, C		118,5, C	
3	161.4, C		160.7, C	
4	115.5, CH	6.79, d (8.6)	115.5, CH	6.79, d (8.6)
5	137.3, CH	7.35, d (8.6)	137.3, CH	7.34, d (8.6)
6	131.0, C		131.0, CH	
7	141.9, C		141.9, C	
8	125.3, CH	6.85, dd (16.1, 1.3)	125.4, CH ₂	6.89, dd (16.0, 1.4)
9	140.1, CH	5.81, dd (16.1, 6.1)	139.9, CH ₂	5.77, dd (16.0, 5.1)
10	76.2, CH	4.13, ddd (6.4, 5.2, 1.4)	76.0, CH	4.15, dq (5.8, 1.4)
11	70.2, CH	3.77, qd (6.2, 5.2)	70.1, CH	3.77, qd (6.4, 5.8)
12	17.8, CH ₃	1.23, d (6.2)	17.6, CH ₃	1.20, d (6.4)
1'	30.6, CH ₂	3.31, d (7.1)	30.6, CH ₂	3.30, d (5.7)
2'	122.4, CH	5.20, t (7.1)	122.4, CH	5.18, t (5.7)
3'	132.3, C		132.3, C	
4'	16.6, CH ₃	1.72, s	16.6, CH ₃	1.72, s
5'	24.5, CH ₃	1.72, s	24.5, CH ₃	1.72, s

Table S2. 1 H (600 MHz) and 13 C NMR (150 MHz) data for compounds 2 and 7 in CD₃OD

Computational details for compound 1-3 (ECD)

The calculations of new compounds 1-3 were performed by using the density functional theory (DFT) as carried out in the Gaussian 09. Conformation search were performed with MMFF94S force fields using Maestro 10.2 software. All these conformers were further optimized by the density functional theory method at the B3LYP/6-31G(d) level. The ECD were calculated using density functional theory (TDDFT) at B3LYP/6-31+G(d) level. The calculated ECD curves were all generated using SpecDis v 1.53 software.

Figure S59. Comparison of the calculated ECD spectra for 1 with the experimental spectrum of 1

Conformer	Energy (hartree)	Ratio (%)
2	-767.7954334	8.62
3	-767.7942924	2.57
4	-767.7959113	14.31
5	-767.7955714	9.98
8	-767.7951577	6.44
9	-767.7948101	4.45
10	-767.7945882	3.52

Table S3. Energy analysis for conformers of 1 at B3LYP/6-31G(d) level

12	-767.7947665	4.25
13	-767.7954791	9.05
14	-767.7951098	6.12
15	-767.7941229	2.15
16	-767.7951059	6.09
21	-767.7946171	3.63
22	-767.7942295	2.41
25	-767.7946866	3.91
27	-767.7942942	2.58
29	-767.7949942	5.41
30	-767.7948158	4.48

Figure S60. Comparison of the calculated ECD spectra for 2 with the experimental

spectrum of 2

67

Conformer	Energy (hartree)	Ratio (%
)
1	-961.9075567	1.71
2	-961.9072757	1.27
6	-961.908038	2.85
8	-961.9081127	3.09
10	-961.9110437	69.09
14	-961.9073732	1.41
16	-961.9073852	1.43
30	-961.9083516	3.98
37	-961.9078313	2.29
42	-961.9081663	3.27
69	-961.9072664	1.26

 Table S4. Energy analysis for conformers of 2 at B3LYP/6-31G(d) level

71	-961.9084103	4.24
81	-961.9080239	2.81
85	-961.9072888	1.29

Figure S61. Comparison of the calculated ECD spectra for **3** with the experimental spectrum of **3**

conformer	Energy (hartree)	Ratio (%
)
1	-691.5644337	66.82
2	-691.5636597	29.42
4	-691.5610731	1.90
5	-691.5610583	1.87

Table S5. Energy analysis for conformers of 1 at B3LYP/6-31G(d) level